Search Results - "A Czibere"

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial by Litton, J.K., Hurvitz, S.A., Mina, L.A., Rugo, H.S., Lee, K.-H., Gonçalves, A., Diab, S., Woodward, N., Goodwin, A., Yerushalmi, R., Roché, H., Im, Y.-H., Eiermann, W., Quek, R.G.W., Usari, T., Lanzalone, S., Czibere, A., Blum, J.L., Martin, M., Ettl, J.

“…In EMBRACA, talazoparib prolonged progression-free survival versus chemotherapy (hazard ratio [HR] 0.542 [95% confidence interval (CI) 0.413-0.711]; P <…”
Get full text

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation by Schroeder, T, Czibere, A, Platzbecker, U, Bug, G, Uharek, L, Luft, T, Giagounidis, A, Zohren, F, Bruns, I, Wolschke, C, Rieger, K, Fenk, R, Germing, U, Haas, R, Kröger, N, Kobbe, G

“…The combination of azacitidine and donor lymphocyte infusions (DLI) as first salvage therapy for relapse after allogeneic transplantation (allo-HSCT) was…”
Get full text

Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation by Schroeder, T, Fröbel, J, Cadeddu, R-P, Czibere, A, Dienst, A, Platzbecker, U, Bug, G, Uharek, L, Fenk, R, Germing, U, Kröger, N, Haas, R, Kobbe, G

Get full text

Core-binding factor leukemia hijacks the T-cell–prone PU.1 antisense promoter by van der Kouwe, E., Heller, G., Czibere, A., Pulikkan, J.A., Agreiter, C., Castilla, L.H., Delwel, R., Di Ruscio, A., Ebralidze, A.K., Forte, M., Grebien, F., Heyes, E., Kazianka, L., Klinger, J., Kornauth, C., Le, T., Lind, K., Barbosa, I.A.M., Pemovska, T., Pichler, A., Schmolke, A.-S., Schweicker, C.M., Sill, H., Sperr, W.R., Spittler, A., Surapally, S., Trinh, B.Q., Valent, P., Vanura, K., Welner, R.S., Zuber, J., Tenen, D.G., Staber, P.B.

“…The blood system serves as a key model for cell differentiation and cancer. It is orchestrated by precise spatiotemporal expression of crucial transcription…”
Get full text

Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial by Yu, Y., Elmeliegy, M., Litton, J.K., Tudor, I.C., Czibere, A., Zheng, J., Wang, D.D.

Get full text

TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on≥1 novel hormonal therapy (NHT) by de Bono, J.S., Higano, C., Saad, F., Miller, K., Casey, M., Czibere, A., Healy, C., Fizazi, K.

Get full text

Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials by Elmeliegy, M., Yu, Y., Litton, J.K., Turner, N.C., Czibere, A., Wilson, G.G., Tudor, I.C., Zheng, J., Wang, D.D.

Get full text

5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis by Czibere, A, Bruns, I, Kröger, N, Platzbecker, U, Lind, J, Zohren, F, Fenk, R, Germing, U, Schröder, T, Gräf, T, Haas, R, Kobbe, G

“…Patients with AML or myelodysplastic syndrome who relapse after allo-SCT have a poor prognosis. In the search for novel treatment strategies for these…”
Get full text

The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence by Bruns, I, Czibere, A, Fischer, J C, Roels, F, Cadeddu, R-P, Buest, S, Bruennert, D, Huenerlituerkoglu, A N, Stoecklein, N H, Singh, R, Zerbini, L F, Jäger, M, Kobbe, G, Gattermann, N, Kronenwett, R, Brors, B, Haas, R

“…We found that composition of cell subsets within the CD34+ cell population is markedly altered in chronic phase (CP) chronic myeloid leukemia (CML)…”
Get full text

Sorafenib (Nexavar® ) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia by Safaian, N.N, Czibere, A, Bruns, I, Fenk, R, Reinecke, P, Dienst, A, Haas, R, Kobbe, G

“…Abstract The fms-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD) can be found in about one quarter of patients with acute myeloid leukemia…”
Get full text

ELRANATAMAB, A B-CELL MATURATION ANTIGEN-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM THE MAGNETISMM-3 STUDY by M Mohty, M Tomasson, B Arnulf, N Bahlis, M Prince, R Niesvizky, P Rodrgue-Otero, J Martine-Lopez, G Koehne, Y Jethava, A Gabayan, D Stevens, A Nooka, N Raje, S Iida, E Leip, U Conte, A Czibere, A Viqueira, V Blunk, A Lesokhin

“…Introduction/Objectives: To report the findings of extended follow-up and biweekly administration of elranatamab monotherapy in patients (pts) with…”
Get full text

Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT by Kobbe, G, Bruns, I, Fenk, R, Czibere, A, Haas, R

“…To date, G-CSF is the most favoured cytokine administered for PBSC mobilization because of its great efficacy and lack of serious toxicity. Recently, a…”
Get full text

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B‐CELL MATURATION ANTIGEN (BCMA)‐CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM‐3 by Lesokhin, A. M., Arnulf, B., Niesvizky, R., Mohty, M., Bahlis, N. J., Tomasson, M. H., Rodrίguez‐Otero, P., Quach, H., Raje, N. S., Iida, S., Raab, M.‐S., Czibere, A., Sullivan, S., Leip, E., Viqueira, A., Leleu, X.

Get full text

Bendamustine in patients with relapsed or refractory multiple myeloma by Michael, M, Bruns, I, Bölke, E, Zohren, F, Czibere, A, Safaian, N N, Neumann, F, Haas, R, Kobbe, G, Fenk, Roland

“…In patients with multiple myeloma, bendamustine monotherapy is effective as 1st and 2nd line therapy. However, data for patients with advanced multiple myeloma…”
Get full text

Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy by Bruennert, D, Czibere, A, Bruns, I, Kronenwett, R, Gattermann, N, Haas, R, Neumann, F

Get full text

A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma by Kobbe, G., Bruns, I., Schroeder, T., Czibere, A., Warnecke, J., Hieronimus, N., Safaian, N., Kondakci, M., Saure, C., Germing, U., Haas, R., Fenk, R.

“…We retrospectively determined whether a 3-day short course of palifermin could reduce the toxicity of high-dose therapy (HDT) and autologous blood stem-cell…”
Get full text

Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases by Zohren, F, Schroeder, T, Czibere, A, Fenk, R, Bruns, I, Kondakci, M, Saure, C, Haas, R, Kobbe, G

“…In the current study, we evaluated a combination of tacrolimus and mycophenolate mofetil (MMF) as GvHD prophylaxis in 50 patients undergoing truly…”
Get full text

Fludarabine, amsacrine, high-dose cytarabine and 12Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia by Zohren, F, Czibere, A, Bruns, I, Fenk, R, Schroeder, T, Graef, T, Haas, R, Kobbe, G

“…In this prospective study, we examined the toxicity and efficacy of an intensified conditioning regimen for treatment of patients with relapsed or high-risk…”
Get full text

O-004 New minimal-invasive diagnostic procedures for patients with myelodysplastic syndromes by profiling the deep serum proteome by Fröbel, J, Hartwig, S, Germing, U, Kündgen, A, Zilkens, C, Schroeder, T, Haas, R, Czibere, A, Lehr, S

Get full text

Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia by Zohren, F, Czibere, A, Bruns, I, Fenk, R, Schroeder, T, Gräf, T, Haas, R, Kobbe, G

“…In this prospective study, we examined the toxicity and efficacy of an intensified conditioning regimen for treatment of patients with relapsed or high-risk…”
Get full text